European Primary Care Cardiovascular Society
EPCCS Annual CV Summit

Heart failure and comorbidities: kidney disease and cancer

5' education - Mar. 22, 2019 - Lisbon, Portugal - Peter van der Meer & Monika Hollander

EPCCS and primary CV care in Poland (Polish)

3' education - Nov. 4, 2019 - Pawel Zuk - EPCCS Council 2019, Bucharest

EPCCS and primary CV care in Poland (English)

3' education - Sep. 13, 2019 - Pawel Zuk - EPCCS 2019, Bucharest

EPCCS and primary CV care in Ukraine

3' education - Sep. 13, 2019 - Maryna Dolzhenko - EPCCS Council 2019

EPCCS and primary CV care in France

3' education - Sep. 13, 2019 - Didier Duhot - EPCCS Council 2019

EPCCS and primary CV care in Ireland

3' education - Sep. 13, 2019 - Cormac Ó Dubhghaill - EPCCS 2019, Bucharest

EPCCS and primary CV care in Turkey

3' education - Sep. 13, 2019 - Zehra Dagli - EPCCS Council 2019, Bucharest

How EPCCS aims to help primary care physicians across Europe in recognizing and managing CV risk (English)

3' education - Sep. 13, 2019 - EPCCS Council Bucharest, Romania - Prof. Christos Lionis

EPCCS and primary CV care in Serbia

3' education - Sep. 13, 2019 - EPCCS Council Bucharest, Romania - Mira Kis-Veljkovic, MD

EPCCS and primary CV care in Spain (Spanish)

3' education - Sep. 13, 2019 - EPCCS Council Bucharest, Romania - Dr. Miguel-Angel Muñoz Pérez

EPCCS and primary CV care in Spain (English)

3' education - Sep. 13, 2019 - EPCCS Council Bucharest, Romania - Dr. Miguel-Angel Muñoz Pérez

EPCCS and primary CV care in Slovakia (Slovak)

3' education - Oct. 3, 2019 - EPCCS Council Bucharest, Romania - Michaela Macháčová, MD

EPCCS and primary CV care in Slovakia (English)

3' education - Oct. 3, 2019 - EPCCS Council Bucharest, Romania - Michaela Macháčová, MD

How EPCCS aims to help primary care physicians across Europe in recognizing and managing CV risk (Greek)

3' education - Sep. 13, 2019 - EPCCS Council Bucharest, Romania - Prof. Christos Lionis

Outreach of EPCCS into European countries: what's in store

3' education - Sep. 13, 2019

Surprising results observed with head-to-head comparison of P2Y12-inhibitors in ACS

3' education - Sep. 16, 2019 - Paris, France - Prof. Stefanie Schüpke

Reduced blood pressure and incidence of hypertension with community-wide salt restriction

3' education - Sep. 16, 2019 - Paris, France - Prof. Jaime Miranda

Reduced CV risk with an intervention targeting identified barriers to care

3' education - Sep. 16, 2019 - Paris, France - Prof. J-D Schwalm

Impact of preventive measures stressed by large community-based studies

3' education - Sep. 16, 2019 - Paris, France - Prof. Salim Yusuf

SGLT2 inhibitor greatly reduced CV risk in HFrEF with or without diabetes

3' education - Sep. 16, 2019 - Paris, France - Prof. John McMurray

Anti-e-cigarette campaign launched by AHA with hashtag #QuitLying addressed to ‘Big Vape’

News - Nov. 18, 2019

AHA 2019 Considering the epidemic of e-cigarette use, particularly among young people, AHA announced substantial investment in research and activities to raise awareness about the risks of vaping.

Lower ischemic events with generic anti-inflammatory drug in patients with recent MI

News - Nov. 18, 2019

AHA 2019 Daily colchicine lowered ischemic events, mostly urgent revascularization, in patients with an MI less than 30 days ago, in the COLCOT trial. Colchicine was well-tolerated.

Superiority of thiazide or thiazide-like diuretics over ACEi as initial monotherapy in hypertension

Literature - Nov. 12, 2019 - Suchard MA, et al. - The Lancet 2019

A study using data of millions of patients showed that there are no differences in effectiveness between drug classes when initiating monotherapy for hypertension, with the exception of lower risk of MI, HHF and stroke with thiazide or thiazide-like diuretics when compared to ACEi.

Heart failure and comorbidities: kidney disease and cancer

5' education - Mar. 22, 2019 - Lisbon, Portugal - Peter van der Meer & Monika Hollander
Monika Hollander asks Peter van der Meer how comorbidities like renal dysfunction and cancer treatment affect management of patients with HF: what is known about treatment in patients with these comorbidities?

EPCCS 2019 Monika Hollander asks Peter van der Meer how comorbidities like renal dysfunction and cancer treatment affects management of patients with HF: what is known about treatment in patients with these comorbidities?

Current data suggest that e-cigarettes are not a harm-free alternative to tobacco smoke

Literature - Nov. 7, 2019 - Buchanan ND et al., - Cardiovasc Res 2019

This review comprehensively summarizes both preclinical and clinical data on the CV effects of e-cigarette use. CV effects of e-cigarette constituents as well as of e-cigarette exposure are reviewed. With poll

EPCCS and primary CV care in Poland (Polish)

3' education - Nov. 4, 2019 - Pawel Zuk - EPCCS Council 2019, Bucharest
A brief impression of how EPCCS activities and plans can be useful for primary care physicians in Poland.

A brief impression of how EPCCS activities and plans can be useful for primary care physicians in Poland.

EPCCS and primary CV care in Ukraine

3' education - Sep. 13, 2019 - Maryna Dolzhenko - EPCCS Council 2019
A brief impression of how EPCCS activities and plans can be useful for primary care physicians in Ukraine.

A brief impression of how EPCCS activities and plans can be useful for primary care physicians in Ukraine.

EPCCS and primary CV care in Turkey

3' education - Sep. 13, 2019 - Zehra Dagli - EPCCS Council 2019, Bucharest
A brief impression of how EPCCS activities and plans can be useful for primary care physicians in Turkey.

A brief impression of how EPCCS activities and plans can be useful for primary care physicians in Turkey.

NAFLD does not automatically mean increased risk of acute MI or stroke

Literature - Nov. 4, 2019 - Alexander M et al, - BMJ 2019

A study of real-world data of 4 large European primary care databases demonstrates that NAFLD is not associated with increased risk of AMI and stroke, after correction for traditional risk factors.

Improved asleep ABP and reduced CVD risk with hypertension medication ingestion at bedtime

Literature - Oct. 31, 2019 - Hermida RC et al., - Eur Heart J 2019

A randomized clinical trial of hypertensive patients demonstrates that ingestion of hypertension medication at bedtime reduces asleep ABP and CVD event risk compared to ingestion upon awakening.

Lower risk of osteoporotic fractures with DOAC use in AF patients

Literature - Oct. 30, 2019 - Binding C, et al. - J Am Coll Cardiol 2019

In a Danish cohort study of nonvalvular AF patients, DOAC use was associated with a lower risk of osteoporotic fractures compared to VKA treatment.

Fish oil: is it all about triglycerides? A debate at ESC 2019

News - Oct. 22, 2019

ESC 2019 Two experts took opposite sides of the statement ‘fish oil: it’s all about triglycerides’ and presented evidence to back up their statements, including data of the REDUCE-IT trial. With poll